| NCT06463665 | Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer | RECRUITING | PHASE2 | 2024-09-26 | 2029-07 | 2027-02 |
| NCT05281471 | Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | RECRUITING | PHASE3 | 2022-08-31 | 2026-10 | 2026-06 |
| NCT02759588 | GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer | COMPLETED | PHASE1, PHASE2 | 2016-05 | 2022-12-31 | 2021-12-31 |
| NCT01584284 | Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer | COMPLETED | PHASE1 | 2012-04 | 2015-07 | 2015-06 |
| NCT01443260 | A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis | COMPLETED | PHASE1, PHASE2 | 2012-02 | 2014-09 | 2014-09 |
| NCT00794131 | Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors | COMPLETED | PHASE1 | 2008-11 | 2015-11 | 2015-11 |